ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

News

News

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.

ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.

A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.

No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.

A study of the combination of radiation therapy and immune checkpoint inhibitors for the treatment of advanced lung cancer found a modest risk of side effects.

Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.

Pages

Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.